Skip Navigation

Oregon Health & Science University

Mail Code UHN73C
3181 Southwest Sam Jackson Park Road
Portland, OR 97239
(503) 494-0672
(888) 222-6478
http://www.ohsu.edu

Number of Transplants Performed

This center has been performing allogeneic transplants since 1991 and has been an NMDP transplant center since June 1996.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
9 89 1 --- 99
Unrelated Donor
- Pediatric
11 3 15 --- 29
Related Donor
- Adult
0 58 0 --- 58
Related Donor
- Pediatric
8 0 0 --- 8
Autologous
- Adult
--- --- --- 187 187
Autologous
- Pediatric
--- --- --- 14 14
Total
(by cell source)
28 150 16 201 395

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Oregon Health and Science University


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 220 patients.

The actual 1-year survival of these patients is 60.8%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 55.4% and 67.5%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).

Pediatric BMT Program, Doernbecher Children's Hospital (OHSU)


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 63 patients.

The actual 1-year survival of these patients is 74.6%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 66.6% and 86.6%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

Oregon Health and Science University - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- 1/1 -- 1/2 2/3 1/2 5/8
Acute lymphoblastic leukemia in second complete remission -- -- -- -- -- 0/1 1/1 1/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 1/1 -- -- -- -- 1/1
Acute myelogenous leukemia in first complete remission -- -- -- 1/2 3/3 1/3 3/4 8/12
Acute myelogenous leukemia in second complete remission -- -- 0/1 -- -- 0/1 -- 0/2
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 0/1 3/4 0/1 3/6
Chronic lymphocytic leukemia and other chronic leukemia -- -- 1/1 -- -- 2/3 -- 3/4
Chronic myelogenous leukemia in first chronic phase -- -- -- 1/1 -- 1/1 -- 2/2
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- -- 0/1 -- 0/1
Hodgkin lymphoma -- -- -- 1/1 -- -- -- 1/1
Multiple myeloma / Plasma cell disorder -- -- -- 1/1 0/1 3/4 -- 4/6
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- -- -- 1/1 1/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- 1/1 -- 2/2 3/3
Myelodysplastic disorders - Other MDS -- -- -- -- -- 1/3 3/3 4/6
Non-Hodgkin lymphoma -- -- 2/2 0/1 4/4 1/2 0/1 7/10
Other acute leukemia -- -- -- -- -- 0/1 -- 0/1
Total -- -- 5/6 4/6 9/12 14/27 11/15 43/66

Oregon Health and Science University - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- -- 2/4 0/1 4/5 2/4 8/14
Acute lymphoblastic leukemia in second complete remission -- -- 1/1 -- -- -- -- 1/1
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/1 -- -- -- -- 0/1
Acute myelogenous leukemia in first complete remission -- -- 1/1 4/5 2/2 4/5 6/17 17/30
Acute myelogenous leukemia in second complete remission -- -- 3/3 1/1 2/3 2/3 4/5 12/15
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- 1/1 -- 0/1 4/8 5/10
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- -- 4/6 3/5 7/11
Chronic myelogenous leukemia in first chronic phase -- -- 1/1 0/1 -- -- -- 1/2
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- 1/2 -- -- 1/2
Chronic myelogenous leukemia in blastic phase -- -- -- -- -- 0/1 -- 0/1
Hodgkin lymphoma -- -- 0/1 1/1 -- -- -- 1/2
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- 2/2 -- -- 3/3 1/5 6/10
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- -- 0/5 2/6 2/11
Myelodysplastic disorders - Other MDS -- -- -- -- 1/1 3/6 1/2 5/9
Myeloproliferative syndromes -- -- -- -- -- 1/1 0/2 1/3
Non-Hodgkin lymphoma -- -- -- 0/1 4/4 3/4 4/6 11/15
Other acute leukemia -- -- 1/1 -- -- -- 0/1 1/2
Severe aplastic anemia -- -- -- -- -- 0/2 0/1 0/3
Total -- -- 9/11 9/14 10/13 24/42 27/62 79/142

Pediatric BMT Program, Doernbecher Children's Hospital (OHSU) - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 2/2 1/1 -- -- -- -- -- 3/3
Acute lymphoblastic leukemia in second complete remission 2/3 0/1 -- -- -- -- -- 2/4
Acute myelogenous leukemia in first complete remission -- 2/3 -- -- -- -- -- 2/3
Disorders of the immune system 1/1 1/1 -- -- -- -- -- 2/2
Inherited abnormalities of erythrocyte differentiation or function 1/1 -- -- -- -- -- -- 1/1
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast 1/1 2/2 -- -- -- -- -- 3/3
Non-Hodgkin lymphoma 1/1 -- -- -- -- -- -- 1/1
Severe aplastic anemia 1/1 4/4 -- -- -- -- -- 5/5
Total 9/10 10/12 -- -- -- -- -- 19/22

Pediatric BMT Program, Doernbecher Children's Hospital (OHSU) - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 2/2 3/4 -- -- -- -- -- 5/6
Acute lymphoblastic leukemia in second complete remission 2/3 -- -- -- -- -- -- 2/3
Acute myelogenous leukemia in first complete remission 2/2 4/6 -- -- -- -- -- 6/8
Acute myelogenous leukemia in second complete remission 3/3 0/1 -- -- -- -- -- 3/4
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure 0/2 -- -- -- -- -- -- 0/2
Disorders of the immune system 2/5 -- -- -- -- -- -- 2/5
Histiocytic disorders 0/1 -- -- -- -- -- -- 0/1
Hodgkin lymphoma -- 0/1 -- -- -- -- -- 0/1
Inherited disorders of metabolism 1/1 -- -- -- -- -- -- 1/1
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- 1/1 -- -- -- -- -- 1/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- 1/1 -- -- -- -- -- 1/1
Non-Hodgkin lymphoma 2/2 -- -- -- -- -- -- 2/2
Other acute leukemia 1/1 1/1 -- -- -- -- -- 2/2
Severe aplastic anemia 0/1 1/1 -- -- -- -- -- 1/2
Total 15/23 11/16 -- -- -- -- -- 26/39

Program Description:

OHSU is a comprehensive FACT-accredited program. Our multidisciplinary approach for the delivery of personalized care of patients is combined with a strong commitment to the conduct of innovative transplant research, optimizing transplant options for residents of Oregon and the Northwest.

Contact Information:

If you have transplant-related questions, please contact Kelli Goslee, transplant center coordinator, at (503) 494-0672 or by e-mail at gosleek@ohsu.edu.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

Andy Chen, Rachel Cook, Kim-Hien T. Dao, James Gajewski, Brandon M. Hayes-Lattin, Richard T. Maziarz, Gabrielle Meyers, Laura Newell, Emma Scott, Stephen E.F. Spurgeon, Elie Traer, Trisha Wong

Pediatric -

Bill Chang, Kristina Haley, Peter Kurre, Thomas Lamkin, Susan Lindemulder, Rebecca Loret de Mola, Suman Malempati, Kellie Nazemi, Eneida Nemecek, H. Stacy Nicholson, Michael Recht, Evan Shereck, Linda Stork, Gregory Thomas, David Tilford, Lawrence J. Wolff

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Tracy Eilers by e-mail at eilerst@ohsu.edu or by phone at (503) 494-5106.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.